About the event
UPDATE FROM FUTURE SCIENCE EVENTS – ORGANISERS OF RWE LIVE
Due to the COVID-19 pandemic, the inaugural RWE LIVE, originally planned for April 2020, was postponed.
We are now very pleased announce that the first in-person RWE LIVE will take place in London (UK) on 29–30 June 2022.
Over the coming months, we will be putting together an exciting new programme ready for June 2022. Ticket sales will open shortly – until then, you can register your interest via the form below to hear about programme updates and be alerted when ticket sales open.
All tickets that were purchased for RWE 2020 will be fully transferable to the new date – we hope that as many of you as possible will still be able to join us then. If you have already registered, we will also be in touch with you directly.
If you have any further questions in the meantime, please contact us via [email protected].
Do you work in the healthcare industry, and need to learn more about how regulatory agencies and HTAs will work with real-world evidence (RWE) for rare diseases? Are you a payer trying to understand the implications of high-cost, innovative treatments? Are you a researcher looking to apply RWE in your work? A patient/patient advocate keen to learn more about the potential real-world data offers to rare disease patients? Or are you a consultant, research organisation or service provider looking to connect with RWE and HEOR experts in industry and academia?
RWE – derived from real-world patient data that are routinely collected from a variety of sources (electronic health records, patient surveys, claims databases, digital devices, and many more) – has the potential to completely alter how decisions are made to regulate, grant access to and pay for healthcare. And nowhere is the potential greater than in the research, diagnosis and treatment of rare diseases, where randomised controlled trials are highly challenging, if not impossible, to conduct, and innovative, high-cost and potentially curative therapies have the potential to turn the standard regulatory, access and reimbursement paradigms upside down.
In response to the need to convene all healthcare stakeholders – pharma, biotech & medical device companies, HTAs and regulators, payers, academics, patient advocacy groups and service providers – we have launched Real-World Evidence 2022: Rare Diseases and Innovative Therapies, in partnership with the Journal of Comparative Effectiveness Research and The Evidence Base®. Over two days, we’ll convene all members of the community who, together, can make the use of RWE in rare diseases and innovative therapies a reality.
As well as providing a platform for the presentation and discussion of ideas, offering the opportunity to connect with other stakeholders is core to the mission of Real-World Evidence 2022: Rare Diseases and Innovative Therapies. The ethos of the event is to facilitate meaningful conversation and then, crucially, support the translation of discussion into action. Communication is key to progressing this field, so over the two days there will be plenty of opportunities to network, meet new contacts and – of course – enjoy a drink at the evening reception!
Who will be there?
- Pharma, biotech & medical device companies
- Regulators and HTAs
- Academics and researchers in RWE, big data and HEOR
- Patient advocacy groups
- Market access specialists
- Medical communications agencies
- HEOR service providers from across the UK and Europe
What will the event look like?
Our mission is to convene a community of collaboration and best practice around the practical application of RWE in rare diseases and innovative therapies, so the event will being together exciting formats to encourage conversation, collaboration and action. Across the 2 days, you can expect a mix of presentations, panels, roundtables, interactive conversations and more…
What will be discussed?
The programme for RWE 2022 is still in the planning, but you can get an idea of the flavour of the event from the themes than were planned for RWE 2020:
- Understanding how RWE can impact on rare diseases
- Coordination and collaboration across Europe for rare disease research
- Understanding the regulatory framework for RWE
- The development of RWE to support drug coverage and formulary decisions
- Value assessment in rare diseases and innovative therapies
- Using RWE to inform clinical trial design in rare diseases
- Achieving transparency in the generation and use of RWE
- Big healthcare data and genomics
- Rare disease registries
- Using mobile devices to gather patient health data
Ticket prices to be announced in due course – watch this space for ticket sales opening..!
Got a question? Contact the RWE 2022 team via [email protected]